AMPH - Amphastar Pharmaceuticals, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

AMPH

AMPHASTAR PHARMACEUTICALS, INC.

NASDAQ

$22.01

▲ UP 0.59% (0.13)

KEY STATISTICS

Market Cap$970.49 M

52w High$31.26

52w Low$16.65

Dividend Yield3.43%

FrequencyAnnual

P/E7.51

Volume224.53K

Shares Out.44.09M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Yongfeng Zhang

COMPENSATION 2026

Salary$950,911

Stock Awards$3,301,981

Incentive Plan Pay$361,000

All Other Comp.$63,687

Total$8,309,350

ABOUT

SECTOR

Healthcare

WENT PUBLIC

June 25, 2014

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

1,976

PRICE TARGET

Target High$23.00

Target Low$19.00

Target Median$21.50

Target Consensus$21.25

UPCOMING EARNINGS

DateNov 5, 2026

DayThursday

Rev. Est.$197.85M

NOV

THU

PRICE

$22.01 ▲ UP 0.59% (+$0.13)

About Amphastar Pharmaceuticals, Inc.

https://www.amphastar.com ↗

Amphastar Pharmaceuticals develops, manufactures, and markets generic and proprietary injectable, inhalation, and intranasal products for healthcare providers in the US, China, and France, serving hospitals, clinics, and care facilities.

INDUSTRY

Drug Manufacturers - Specialty & Generic

A PRODUCT AMPHASTAR PHARMACEUTICALS, INC. IS KNOWN FOR

Baqsimi® (glucagon) nasal powder 3mg

Baqsimi, the first nasal glucagon for severe hypoglycemia, was acquired from Eli Lilly in 2023 for over $1 billion, strengthening Amphastar's diabetes care portfolio with a needle-free emergency treatment.

COMPETITORS

COMPETITOR

Revenue by Products

PRODUCT	Q3-2025	Q4-2025	Q1-2026	Q2-2026
Total product revenues net	$191.84M	—	—	—
Other Products	$64.14M	—	$67.13M ▲	$66.19M ▼
BAQSIMI	$53.61M	—	$32.43M ▼	$45.5M ▲
Primatene MIST	$28.81M	—	$29.76M ▲	$21M ▼
Epinephrine	$18.79M	$35.67M ▲	$19.21M ▼	$15.85M ▼
Lidocaine	$12.93M	—	$13.46M ▲	$15.04M ▲
Glucagon	$13.56M	—	$9.17M ▼	$11.9M ▲
Ipratropium Bromide Member	—	—	—	$8.41M